| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Cryptochromes (CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer.
|
|---|---|
| ln Vitro |
The restoration of E-box-driven luciferase activity was observed at varying dosages of KS15, ranging from μM to 10 μM. This suggests that KS15 carries the transcriptional effects of CRY CLOCK:BMAL1 reversal regulation. The C-terminal region of cryptochromes (CRYs: CRY1 and CRY2) is directly bound by KS15, which also increases E-box-mediated transcription. This results in a considerable inhibition of transcription between CRYs and BMAL1 [2]. Cell development is slowed by KS15. MCF-7 cells' speed and chemical strength are increased in response to doxorubicin and tamoxifen. For some forms of breast cancer, KS15 improves the hardness of anti-tumor medications and has anti-ischemic properties [2].
KS15 is an inhibitor of the interaction between cryptochromes and the CLOCK:BMAL1 heterodimer. It impairs the feedback actions of CRYs on E-box-dependent transcription with an EC50 of 4.9 μM. The compound has anti-proliferative activity and increases sensitivity to anti-tumor drugs in breast cancer cells. It promotes G1 cell cycle arrest. |
| ln Vivo |
In vivo efficacy of KS15 has not been extensively characterized in publicly available literature. As a modulator of the circadian clock with anti-proliferative activity, it may have potential in cancer research. The compound's ability to increase sensitivity to anti-tumor drugs suggests potential for combination therapies.
|
| Enzyme Assay |
The inhibition of CRY-CLOCK:BMAL1 interaction is assessed using in vitro biochemical or cell-based assays. The interaction between CRY and CLOCK:BMAL1 is measured by co-immunoprecipitation or FRET-based assays in the presence of varying concentrations of KS15. The inhibition of E-box-dependent transcription is measured using a luciferase reporter assay.
|
| Cell Assay |
Cellular activity is evaluated in cancer cell lines, such as breast cancer cells. Cells are treated with KS15, and cell proliferation is measured by MTT or CellTiter-Glo assays. Cell cycle distribution is analyzed by flow cytometry. The expression of circadian clock genes and the sensitivity to anti-tumor drugs are assessed.
|
| Animal Protocol |
In vivo studies for KS15 are limited. Potential studies could be conducted in mouse xenograft models of cancer. KS15 would be administered orally or intraperitoneally, and tumor growth would be measured. The compound's ability to enhance the efficacy of anti-tumor drugs would be assessed in combination studies.
|
| ADME/Pharmacokinetics |
KS15 has a molecular formula of C20H22BrNO4 and a molecular weight of 420.30 g/mol. It is a small molecule inhibitor. The compound is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for KS15 are not extensively published. As a modulator of the circadian clock, it may have effects on circadian rhythms and cellular proliferation. The compound is for research use only.
|
| References |
|
| Additional Infomation |
KS15 is a research tool compound for studying the circadian clock and its role in cancer. It is not approved for clinical use. The compound is an inhibitor of CRY-CLOCK:BMAL1 interaction with an EC50 of 4.9 μM. It has anti-proliferative activity.
|
| Molecular Formula |
C20H22BRNO4
|
|---|---|
| Molecular Weight |
420.30
|
| Exact Mass |
419.073
|
| CAS # |
1033781-20-2
|
| PubChem CID |
25114872
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC=C(C=C1C[C@H](C(=O)O)OCC)/C(/C)=N/OCC1=CC=C(C=C1)Br
|
| InChi Key |
GWSVRVKPZVYTCS-VZMFNRANSA-N
|
| InChi Code |
InChI=1S/C20H22BrNO4/c1-3-25-19(20(23)24)12-16-5-4-6-17(11-16)14(2)22-26-13-15-7-9-18(21)10-8-15/h4-11,19H,3,12-13H2,1-2H3,(H,23,24)/b22-14+/t19-/m1/s1
|
| Chemical Name |
(2R)-3-[3-[(E)-N-[(4-bromophenyl)methoxy]-C-methylcarbonimidoyl]phenyl]-2-ethoxypropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~237.93 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.95 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3793 mL | 11.8963 mL | 23.7925 mL | |
| 5 mM | 0.4759 mL | 2.3793 mL | 4.7585 mL | |
| 10 mM | 0.2379 mL | 1.1896 mL | 2.3793 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
